A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  NMCD. Nutrition Metabolism and Cardiovascular Diseases

• Publication date

  2016-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.numecd.2015.11.004PMID 27033025
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease.

  2014cited by this paper
• Erratum: ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD (European Heart Journal (2013) 34 (3035-3087) Doi:10.1093/eurheartj/eht108)

  2014cited by this paper
• UNIVERSITE DE LAUSANNE-FACULTE DE BIOLOGIE ET DE MEDECINE

  2014cited by this paper
• Saxagliptin Efficacy and Safety in Patients with Type 2 Diabetes Mellitus Stratified by Cardiovascular Disease History and Cardiovascular Risk Factors: Analysis of 3 Clinical Trials

  2014cited by this paper
• Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases

  2014cited by this paper
• Adiposity markers and risk of coronary heart disease in patients with type 2 diabetes mellitus

  2014cited by this paper
• Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease History or Cardiovascular Risk Factors: Results of a Pooled Analysis of Phase 3 Clinical Trials

  2013cited by this paper
• The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial

  2012cited by this paper
• Diabetes and hypertension: the bad companions.

  2012cited by this paper
• Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

  2012cited by this paper
• Hypoglycemia and Cardiovascular Risks

  2011cited by this paper
• Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations

  2011cited by this paper
• Cardiovascular Risk Prediction Is Improved by Adding Asymptomatic Coronary Status to Routine Risk Assessment in Type 2 Diabetic Patients

  2011cited by this paper
• Hypoglycemia, Diabetes, and Cardiovascular Events

  2010cited by this paper
• Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

  2009cited by this paper
• Cardiovascular risk assessment scores for people with diabetes: a systematic review

  2009cited by this paper
• Defining and Characterizing the Progression of Type 2 Diabetes

  2009cited by this paper
• The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone

  2009cited by this paper
• Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone.

  2009cited by this paper
• Impact of using a non-diabetes-specific risk calculator on eligibility for statin therapy in type 2 diabetes

  2009cited by this paper
• Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

  2009cited by this paper
• Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in Estimating Cardiovascular Disease in the EPIC- Norfolk Cohort

  2008cited by this paper
• Predictive value of coronary calcifications for future cardiac events in asymptomatic patients with diabetes mellitus: A prospective study in 716 patients over 8 years

  2008cited by this paper
• Differences in Glucose Tolerance Between Fixed-Dose Antihypertensive Drug Combinations in People With Metabolic Syndrome

  2007cited by this paper
• Errata

  2007cited by this paper
• Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.

  2007cited by this paper
• Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis.

  2007cited by this paper
• Standards of Medical Care in Diabetes: Response to Power

  2006cited by this paper
• Aging and insulin secretion.

  2003cited by this paper
• UKPDS 60: Risk of Stroke in Type 2 Diabetes Estimated by the UK Prospective Diabetes Study Risk Engine

  2002cited by this paper
• The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56).

  2001cited by this paper

• Self‐management among type 2 diabetes patients via the WeChat application: A systematic review and meta‐analysis

  2020cites this paper
• Qizhi Decoction may Protect Diabetic Nephropathy Through Decrease Lipid and Inflammation

  2018cites this paper
• Pre diabetes como factor de riesgo en el síndrome coronario agudo

  2017cites this paper